Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study

Juliane Maria Doepfner,1 Stephan Michels,1,2 Nicole Graf,3 Matthias Dieter Becker,1 Florentina Joyce Freiberg1 1Department of Ophthalmology, Triemli City Hospital, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland; 3Graf Biostatistics, Winterthur, Switzerland Pur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Doepfner JM, Michels S, Graf N, Becker MD, Freiberg FJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	central serous chorioretinopathy - photodynamic therapy - anti-VEGF - subretinal fluid Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/83b9d6f8222240a683f21a0e739a7d63
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83b9d6f8222240a683f21a0e739a7d63
record_format	dspace
spelling	oai:doaj.org-article:83b9d6f8222240a683f21a0e739a7d632021-12-02T03:07:33ZPhotodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study1177-5483https://doaj.org/article/83b9d6f8222240a683f21a0e739a7d632018-07-01T00:00:00Zhttps://www.dovepress.com/photodynamic-therapy-in-combination-with-intravitreal-ziv-aflibercept--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Juliane Maria Doepfner,1 Stephan Michels,1,2 Nicole Graf,3 Matthias Dieter Becker,1 Florentina Joyce Freiberg1 1Department of Ophthalmology, Triemli City Hospital, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland; 3Graf Biostatistics, Winterthur, Switzerland Purpose: The objective of the study was to assess the effect of off-label photodynamic therapy (PDT) in combination with intravitreal off-label ziv-aflibercept or off-label aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy (CSC).Patients and methods: Changes in best corrected visual acuity (BCVA) and subfoveal subretinal fluid (sSRF) and maximum subretinal fluid (mSRF) were retrospectively analyzed in a single-center cohort study of 17 patients (18 eyes) with persistent subretinal fluid for more than 3 months of duration of CSC. Treatment efficacy was measured between injection and PDT at 30±15 days, 90±15 days and 180±30 days after PDT.Results: Significant reduction of sSRF and mSRF was shown after therapy with ziv-aflibercept and aflibercept combined with PDT (p<0.001). Course of BCVA showed non-significant improvement within 6 months (p=0.065). One case of allergic reaction after fluorescein angiography and one case of ophthalmic migraine after ziv-aflibercept injection were documented. One case of reversible vision loss occurred during 6 months after combination therapy. No other adverse events or side effects were reported.Conclusion: Combination therapy of ziv-aflibercept and aflibercept with PDT seems to be beneficial, even in cases of chronic or repeatedly recurrent acute CSC. This includes cases of CSC resistant to or recurrent after medical treatment, PDT alone or therapy with anti-vascular endothelial growth factor alone. Keywords: therapy-refractory, combination therapy, anti-VEGF, subretinal fluidDoepfner JMMichels SGraf NBecker MDFreiberg FJDove Medical Pressarticlecentral serous chorioretinopathy - photodynamic therapy - anti-VEGF - subretinal fluidOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 1301-1309 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	central serous chorioretinopathy - photodynamic therapy - anti-VEGF - subretinal fluid Ophthalmology RE1-994
spellingShingle	central serous chorioretinopathy - photodynamic therapy - anti-VEGF - subretinal fluid Ophthalmology RE1-994 Doepfner JM Michels S Graf N Becker MD Freiberg FJ Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
description	Juliane Maria Doepfner,1 Stephan Michels,1,2 Nicole Graf,3 Matthias Dieter Becker,1 Florentina Joyce Freiberg1 1Department of Ophthalmology, Triemli City Hospital, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland; 3Graf Biostatistics, Winterthur, Switzerland Purpose: The objective of the study was to assess the effect of off-label photodynamic therapy (PDT) in combination with intravitreal off-label ziv-aflibercept or off-label aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy (CSC).Patients and methods: Changes in best corrected visual acuity (BCVA) and subfoveal subretinal fluid (sSRF) and maximum subretinal fluid (mSRF) were retrospectively analyzed in a single-center cohort study of 17 patients (18 eyes) with persistent subretinal fluid for more than 3 months of duration of CSC. Treatment efficacy was measured between injection and PDT at 30±15 days, 90±15 days and 180±30 days after PDT.Results: Significant reduction of sSRF and mSRF was shown after therapy with ziv-aflibercept and aflibercept combined with PDT (p<0.001). Course of BCVA showed non-significant improvement within 6 months (p=0.065). One case of allergic reaction after fluorescein angiography and one case of ophthalmic migraine after ziv-aflibercept injection were documented. One case of reversible vision loss occurred during 6 months after combination therapy. No other adverse events or side effects were reported.Conclusion: Combination therapy of ziv-aflibercept and aflibercept with PDT seems to be beneficial, even in cases of chronic or repeatedly recurrent acute CSC. This includes cases of CSC resistant to or recurrent after medical treatment, PDT alone or therapy with anti-vascular endothelial growth factor alone. Keywords: therapy-refractory, combination therapy, anti-VEGF, subretinal fluid
format	article
author	Doepfner JM Michels S Graf N Becker MD Freiberg FJ
author_facet	Doepfner JM Michels S Graf N Becker MD Freiberg FJ
author_sort	Doepfner JM
title	Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
title_short	Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
title_full	Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
title_fullStr	Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
title_full_unstemmed	Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
title_sort	photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/83b9d6f8222240a683f21a0e739a7d63
work_keys_str_mv	AT doepfnerjm photodynamictherapyincombinationwithintravitrealzivafliberceptandafliberceptinjectioninpatientswithchronicorrepeatedlyrecurrentacutecentralserouschorioretinopathyasinglecenterretrospectivestudy AT michelss photodynamictherapyincombinationwithintravitrealzivafliberceptandafliberceptinjectioninpatientswithchronicorrepeatedlyrecurrentacutecentralserouschorioretinopathyasinglecenterretrospectivestudy AT grafn photodynamictherapyincombinationwithintravitrealzivafliberceptandafliberceptinjectioninpatientswithchronicorrepeatedlyrecurrentacutecentralserouschorioretinopathyasinglecenterretrospectivestudy AT beckermd photodynamictherapyincombinationwithintravitrealzivafliberceptandafliberceptinjectioninpatientswithchronicorrepeatedlyrecurrentacutecentralserouschorioretinopathyasinglecenterretrospectivestudy AT freibergfj photodynamictherapyincombinationwithintravitrealzivafliberceptandafliberceptinjectioninpatientswithchronicorrepeatedlyrecurrentacutecentralserouschorioretinopathyasinglecenterretrospectivestudy
_version_	1718401928226930688

Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study

Ejemplares similares